Phase II breast cancer chemoprevention study with celecoxib in women at increased risk for breast cancer.

Abstract

1010 Background: Short-term chemoprevention trials offer a convenient model to screen chemopreventive agents and identify endpoint biomarkers. One of the potential agents is celecoxib (C), which has antiproliferative and apoptosis inducing properties. In this prospective study, our primary aim was to evaluate changes in proliferation induced by C in breast… (More)

Topics

Cite this paper

@article{Arun2006PhaseIB, title={Phase II breast cancer chemoprevention study with celecoxib in women at increased risk for breast cancer.}, author={Banu K. Arun and Vicente Valero and G. Yin and Gildy V. Babiera and J. L. Murray and Duncan Browne and Yan Gong and El{\'i}sabet Cook and G. N. Hortobagyi and Nour Sneige}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2006}, volume={24 18_suppl}, pages={1010} }